08:55 AM EDT, 09/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday the US Food and Drug Administration approved Tremfya for plaque psoriasis or active psoriatic arthritis for children aged six and older.

The decision was supported by the phase 3 Protostar study showing higher week 16 skin-clearance rates versus placebo in pediatric plaque psoriasis, the company said.

For these pediatric uses, dosing is 100 mg by injection at week 0, week 4 then every eight weeks, JNJ said.